S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

$14.66
+0.51 (+3.60%)
(As of 03/27/2024 ET)
Today's Range
$13.73
$15.16
50-Day Range
$8.48
$28.10
52-Week Range
$6.81
$29.70
Volume
166,883 shs
Average Volume
254,544 shs
Market Capitalization
$304.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.67

Adverum Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.5% Upside
$34.67 Price Target
Short Interest
Healthy
4.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.78mentions of Adverum Biotechnologies in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$135,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.67 out of 5 stars

Medical Sector

73rd out of 939 stocks

Biological Products, Except Diagnostic Industry

12th out of 151 stocks

ADVM stock logo

About Adverum Biotechnologies Stock (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Stock Price History

ADVM Stock News Headlines

Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $14.75
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Adverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $2.00
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen
ADVM Adverum Biotechnologies, Inc.
ADVM Apr 2024 5.000 call
Stocks on the Launchpad: The Next 3 Market Sensations
Unleash Massive Returns With These 3 Top Penny Stocks
ADVM Feb 2024 4.000 call
ADVM Sep 2024 2.500 put
Adverum Biotechnologies Inc (ADVM)
See More Headlines
Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADVM
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.67
High Stock Price Target
$60.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+136.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-117,170,000.00
Pretax Margin
-3,284.53%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$8.26 per share

Miscellaneous

Free Float
19,655,000
Market Cap
$304.20 million
Optionable
Optionable
Beta
0.88
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Laurent FischerDr. Laurent Fischer (Age 60)
    President, CEO & Director
    Comp: $1.02M
  • Ms. Linda M. Rubinstein M.A. (Age 57)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $940.99k
  • Ms. Dena House
    Chief People Officer
  • Ms. Carla Fiankan
    Senior Vice President of Regulatory Affairs
  • Mr. Michael Steel
    Senior Vice President of Quality
  • Mr. Heikki Jouttijarvi
    Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations
  • Mr. Anand Reddi (Age 41)
    VP and Head of Corporate Strategy & External Affairs & Engagement
  • Dr. Bill Tan Pharm.D.
    Senior VP & Head of Global Clinical Operations
  • Dr. Kalliopi Stasi M.D.
    Ph.D., Senior Vice President of Clinical Development

ADVM Stock Analysis - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADVM shares.
View ADVM analyst ratings
or view top-rated stocks.

What is Adverum Biotechnologies' stock price target for 2024?

3 equities research analysts have issued 1 year price objectives for Adverum Biotechnologies' stock. Their ADVM share price targets range from $4.00 to $60.00. On average, they expect the company's share price to reach $34.67 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price.
View analysts price targets for ADVM
or view top-rated stocks among Wall Street analysts.

How have ADVM shares performed in 2024?

Adverum Biotechnologies' stock was trading at $7.5280 on January 1st, 2024. Since then, ADVM stock has increased by 94.7% and is now trading at $14.66.
View the best growth stocks for 2024 here
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 648,500 shares, a decline of 88.1% from the February 29th total of 5,430,000 shares. Based on an average daily volume of 231,700 shares, the days-to-cover ratio is currently 2.8 days. Currently, 4.3% of the shares of the stock are short sold.
View Adverum Biotechnologies' Short Interest
.

When is Adverum Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ADVM earnings forecast
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) posted its quarterly earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) EPS for the quarter, topping analysts' consensus estimates of ($2.80) by $0.50.

When did Adverum Biotechnologies' stock split?

Adverum Biotechnologies's stock reverse split on the morning of Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (4.51%), AIGH Capital Management LLC (3.14%), Newtyn Management LLC (0.81%), Worth Venture Partners LLC (0.78%), Dimensional Fund Advisors LP (0.19%) and Twin Focus Capital Partners LLC (0.10%). Insiders that own company stock include Brigit Riley, Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi.
View institutional ownership trends
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADVM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners